JP5161584B2 - 化学的方法 - Google Patents

化学的方法 Download PDF

Info

Publication number
JP5161584B2
JP5161584B2 JP2007546172A JP2007546172A JP5161584B2 JP 5161584 B2 JP5161584 B2 JP 5161584B2 JP 2007546172 A JP2007546172 A JP 2007546172A JP 2007546172 A JP2007546172 A JP 2007546172A JP 5161584 B2 JP5161584 B2 JP 5161584B2
Authority
JP
Japan
Prior art keywords
azd0530
mixture
compound
formula
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2007546172A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008524183A (ja
JP2008524183A5 (https=
Inventor
フォード，ジェームズ・ゲア
マッケイブ，ジェームズ・フランシス
オキアニー−マクミュラン，アン
オキーフェ，フィリップ
ポイントン，サイモン・マーク
パウエル，リン
パーディー，マーク
ウィズノール，ジェーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2008524183A publication Critical patent/JP2008524183A/ja
Publication of JP2008524183A5 publication Critical patent/JP2008524183A5/ja
Application granted granted Critical
Publication of JP5161584B2 publication Critical patent/JP5161584B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2007546172A 2004-12-17 2005-12-14 化学的方法 Expired - Lifetime JP5161584B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0427697.8 2004-12-17
GBGB0427697.8A GB0427697D0 (en) 2004-12-17 2004-12-17 Chemical process
PCT/GB2005/004807 WO2006064217A2 (en) 2004-12-17 2005-12-14 PROCESS FOR THE PREPARATION OF 4-(6-CHLORO-2, 3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-l-YL) ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE , THEIR INTERMEDIATES AND CRYSTALLINE SALTS THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008318186A Division JP2009143920A (ja) 2004-12-17 2008-12-15 化学的方法

Publications (3)

Publication Number Publication Date
JP2008524183A JP2008524183A (ja) 2008-07-10
JP2008524183A5 JP2008524183A5 (https=) 2009-02-19
JP5161584B2 true JP5161584B2 (ja) 2013-03-13

Family

ID=34090249

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007546172A Expired - Lifetime JP5161584B2 (ja) 2004-12-17 2005-12-14 化学的方法
JP2008318186A Pending JP2009143920A (ja) 2004-12-17 2008-12-15 化学的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008318186A Pending JP2009143920A (ja) 2004-12-17 2008-12-15 化学的方法

Country Status (16)

Country Link
US (1) US8304417B2 (https=)
EP (1) EP1871769B1 (https=)
JP (2) JP5161584B2 (https=)
KR (6) KR20080094847A (https=)
CN (1) CN101115744B (https=)
AU (2) AU2005315458B2 (https=)
BR (1) BRPI0519085A2 (https=)
CA (2) CA2590735C (https=)
ES (1) ES2622480T3 (https=)
GB (1) GB0427697D0 (https=)
IL (1) IL183525A0 (https=)
MX (1) MX2007007210A (https=)
NO (1) NO20072755L (https=)
NZ (1) NZ555468A (https=)
WO (1) WO2006064217A2 (https=)
ZA (1) ZA200704532B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412074D0 (en) * 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
WO2009068906A2 (en) * 2007-11-26 2009-06-04 Astrazeneca Ab Combinations comprising zd4054 and a src family kinase inhibitor 172
CN103275072B (zh) * 2013-05-22 2016-01-20 苏州明锐医药科技有限公司 塞卡替尼的制备方法
US11241434B2 (en) 2013-06-13 2022-02-08 Yale Uninversity Compositions and methods for improving cognition in a subject
US10660957B2 (en) * 2013-06-13 2020-05-26 Yale University Compositions and methods for treating an Aβ-modulated disease or disorder or improving cognition in a subject
US10369152B2 (en) 2015-02-13 2019-08-06 The Brigham And Women's Hospital, Inc. Methods and compositions for the treatment or prevention of abnormal bone formation in a soft tissue
PT3930715T (pt) 2019-02-27 2024-08-02 Astrazeneca Ab Saracatinib para uso no tratamento de fibrose pulmonar idiopática
CN116332789A (zh) * 2023-03-10 2023-06-27 上海康鹏科技股份有限公司 一种4-氨基-2-氟苯甲酰胺的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
CA2419301C (en) 2000-08-21 2009-12-08 Astrazeneca Ab Quinazoline derivatives
DE60229046D1 (de) 2001-04-19 2008-11-06 Astrazeneca Ab Chinazolin derivate
RU2350618C2 (ru) 2002-11-04 2009-03-27 Астразенека Аб ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
GB0226434D0 (en) 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
GB0307333D0 (en) 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent

Also Published As

Publication number Publication date
ZA200704532B (en) 2008-07-30
CN101115744A (zh) 2008-01-30
KR20080094847A (ko) 2008-10-24
US8304417B2 (en) 2012-11-06
EP1871769A2 (en) 2008-01-02
KR20080094846A (ko) 2008-10-24
KR20110114727A (ko) 2011-10-19
US20090099196A1 (en) 2009-04-16
CA2675642A1 (en) 2006-06-22
EP1871769B1 (en) 2017-02-22
KR20080094849A (ko) 2008-10-24
AU2005315458B2 (en) 2009-03-12
AU2005315458A1 (en) 2006-06-22
CA2590735C (en) 2009-11-10
BRPI0519085A2 (pt) 2008-12-23
NZ555468A (en) 2010-12-24
WO2006064217A3 (en) 2006-12-21
WO2006064217A2 (en) 2006-06-22
WO2006064217A8 (en) 2007-07-05
MX2007007210A (es) 2007-11-07
IL183525A0 (en) 2007-09-20
AU2009200622A1 (en) 2009-03-12
KR20070090004A (ko) 2007-09-04
JP2008524183A (ja) 2008-07-10
CA2590735A1 (en) 2006-06-22
CN101115744B (zh) 2012-02-01
JP2009143920A (ja) 2009-07-02
NO20072755L (no) 2007-07-02
ES2622480T3 (es) 2017-07-06
KR20080094848A (ko) 2008-10-24
GB0427697D0 (en) 2005-01-19

Similar Documents

Publication Publication Date Title
JP4836404B2 (ja) 抗癌化合物ｚｄ１８３９の新規結晶形
JP2009143920A (ja) 化学的方法
CN102123989A (zh) 吡唑化合物436
US10561646B2 (en) EGFR inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof
PL208708B1 (pl) Polimorficzne formy chlorowodorku 1-4-(5-cyjanoindolo-3 -ylo) butylo-4- (2-karbamoilobenzofurano-5-ylo) piperazyny, sposób ich otrzymywania, ich zastosowanie w terapii zaburzeń medycznych i zawierające je kompozycje farmaceutyczne
KR20190133724A (ko) (S)-2-((2-((S)-4-(다이플루오로메틸)-2-옥소옥사졸리딘-3-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)아미노)프로판아미드의 다형체 및 고체 형태, 및 이의 제조 방법
CN1854130B (zh) 喹唑啉衍生物、及其制法和药物组合物与用途
HK40105057A (zh) 一类用作激酶抑制剂的化合物及其应用
HK40105057B (zh) 一类用作激酶抑制剂的化合物及其应用
JP2008521810A (ja) （２ｓ）−１−［［（７ｒ）−７−（３，４−ジクロロフェニル）−４，７−ジヒドロ−５−メチルピラゾロ［１，５］ピリミジン−６−イル］カルボニル］−２−（４−フルオロフェニル）ピロリジンの新規な結晶形の製造方法、該製造方法において製造される新規な安定な結晶形、および製剤
HK40037665A (en) Egfr inhibitors
HK1070582B (en) Novel crystalline forms of the anti-cancer compound zd1839

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081215

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120517

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120928

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20121009

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121214

R150 Certificate of patent or registration of utility model

Ref document number: 5161584

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151221

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term